The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Long-term Renal Outcomes of Patients With Type 1 Diabetes Mellitus and Microalbuminuria<subtitle>An Analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Cohort</subtitle><alt-title>Microalbuminuria Outcomes in Type 1 Diabetes</alt-title>
Open accessAbstract
BACKGROUND: Microalbuminuria is a common diagnosis in the clinical care of patients with type 1 diabetes mellitus. Long-term outcomes after the development of microalbuminuria are variable. METHODS: We quantified the incidence of and risk factors for long-term renal outcomes after the development of microalbuminuria in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. The DCCT randomly assigned 1441 persons with type 1 diabetes to intensive or conventional diabetes therapy, and participants were subsequently followed up during the observational EDIC study. During the DCCT/EDIC study, 325 participants developed incident persistent microalbuminuria (albumin excretion rate, ≥30 mg/24 h at 2 consecutive study visits). We assessed their subsequent renal outcomes, including progression to macroalbuminuria (albumin excretion rate, ≥300 mg/24 h at 2 consecutive visits), impaired glomerular filtration rate (estimated glomerular filtration rate, <60 mL/min/1.73 m(2) at 2 consecutive study visits), end-stage renal disease, and regression to normoalbuminuria (albumin excretion rate, <30 mg/24 h at 2 consecutive visits). RESULTS: The median follow-up period after persistent microalbuminuria diagnosis was 13 years (maximum, 23 years). Ten-year cumulative incidences of progression to macroalbuminuria, impaired glomerular filtration rate, end-stage renal disease, and regression to normoalbuminuria were 28%, 15%, 4%, and 40%, respectively. Albuminuria outcomes were more favorable with intensive diabetes therapy, lower glycated hemoglobin level, absence of retinopathy, female sex, lower blood pressure, and lower concentrations of low-density lipoprotein cholesterol and triglycerides. Lower glycated hemoglobin level, absence of retinopathy, and lower blood pressure were also associated with decreased risk of impaired glomerular filtration rate. CONCLUSIONS: After the development of persistent microalbuminuria, progression and regression of kidney disease each commonly occur. Intensive glycemic control, lower blood pressure, and a more favorable lipid profile are associated with improved outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Basevi, V., Di Mario, S., Morciano, C., Nonino, F., & Magrini, N. (2011) · Diabetes Care · doi:10.2337/dc11-0174 · Cited by 3,055
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Parving, H., Lehnert, H., Brøchner‐Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · PubMed · Cited by 2,535
Standards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167
Microalbuminuria Predicts Clinical Proteinuria and Early Mortality in Maturity-Onset Diabetes
Mogensen, C. E. (1984) · New England Journal of Medicine · doi:10.1056/nejm198402093100605 · Cited by 1,908
The Empirical Distribution Function with Arbitrarily Grouped, Censored and Truncated Data
Turnbull, B. W. (1976) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1976.tb01597.x · Cited by 1,828
Cited by
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Atkinson, M. A., Eisenbarth, G. S., & Michels, A. W. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60591-7 · Cited by 2,931
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht108 · Cited by 1,955
Lurbe, E., Agabiti-Rosei, E., Cruickshank, J. K., Dominiczak, A., Erdine, S., Hirth, A., Invitti, C., Litwin, M., Mancia, G., Pall, D., et al. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000001039 · Cited by 1,379
KDOQI clinical practice guideline for diabetes and CKD: 2012 update
(2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.005 · Cited by 1,320
Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014
Afkarian, M., Zelnick, L. R., Hall, Y. N., Heagerty, P. J., Tuttle, K., Weiss, N. S., & de Boer, I. H. (2016) · JAMA · doi:10.1001/jama.2016.10924 · Cited by 1,026
Self-citationMolecular mechanisms of diabetic kidney disease
Reidy, K., Kang, H. M., Hostetter, T., & Susztak, K. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72271 · Cited by 909
The Global Epidemiology of Diabetes and Kidney Disease
Koye, D. N., Magliano, D. J., Nelson, R. G., & Pavkov, M. E. (2018) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2017.10.011 · Cited by 686
Laiteerapong, N., Ham, S. A., Gao, Y., Moffet, H. H., Liu, J. Y., Huang, E. S., & Karter, A. J. (2019) · Diabetes Care · doi:10.2337/dc17-1144 · Cited by 574
Update of pathophysiology and management of diabetic kidney disease
Lin, Y.-C., Chang, Y.-H., Yang, S.-Y., Wu, K.-D., & Chu, T.-S. (2018) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2018.02.007 · Cited by 562
Diabetic Microvascular Disease: An Endocrine Society Scientific Statement
Barrett, E. J., Liu, Z., Khamaisi, M., King, G. L., Klein, R., Klein, B. E. K., Hughes, T. M., Craft, S., Freedman, B. I., Bowden, D. W., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01922 · Cited by 515
de Ferranti, S. D., de Boer, I. H., Fonseca, V., Fox, C. S., Golden, S. H., Lavie, C. J., Magge, S. N., Marx, N., McGuire, D. K., Orchard, T. J., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000034 · Cited by 503
Self-citationde Ferranti, S. D., de Boer, I. H., Fonseca, V., Fox, C. S., Golden, S. H., Lavie, C. J., Magge, S. N., Marx, N., McGuire, D. K., Orchard, T. J., et al. (2014) · Diabetes Care · doi:10.2337/dc14-1720 · Cited by 433
Self-citationEpidemiology of Diabetic Kidney Disease
Reutens, A. T. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.10.001 · Cited by 326
Diabetic Nephropathy: New Risk Factors and Improvements in Diagnosis
Tziomalos, K., & Athyros, V. G. (2015) · The Review of Diabetic Studies · doi:10.1900/rds.2015.12.110 · Cited by 268
de Boer, I. H., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2113 · Cited by 254
(2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70155-x · Cited by 183
Cost and cost-effectiveness of large-scale screening for type 1 diabetes in Colorado
McQueen, R. B., Geno Rasmussen, C., Waugh, K., Frohnert, B. I., Steck, A. K., Yu, L., Baxter, J., & Rewers, M. (2020) · Diabetes Care · doi:10.2337/dc19-2003 · Cited by 138
Albuminuria changes and cardiovascular and renal outcomes in type 1 diabetes: the DCCT/EDIC study
de Boer, I. H., Gao, X., Cleary, P. A., Bebu, I., Lachin, J. M., Molitch, M. E., Orchard, T., Paterson, A. D., Perkins, B. A., Steffes, M. W., et al. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02870316 · Cited by 114
Glucose targets for preventing diabetic kidney disease and its progression
Ruospo, M., Saglimbene, V. M., Palmer, S. C., De Cosmo, S., Pacilli, A., Lamacchia, O., Cignarelli, M., Fioretto, P., Vecchio, M., Craig, J. C., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010137.pub2 · Cited by 111
Akturk, H. K., Snell-Bergeon, J. K., Rewers, A., Klaff, L. J., Bode, B. W., Peters, A. L., Bailey, T. S., & Garg, S. K. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0200 · Cited by 70
Heerspink, H. J. L., Birkenfeld, A. L., Cherney, D. Z. I., Colhoun, H. M., Ji, L., Mathieu, C., Groop, P.-H., Pratley, R. E., Rosas, S. E., Rossing, P., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110908 · Cited by 63
Romero-Aroca, P., Baget-Bernaldiz, M., Reyes-Torres, J., Fernandez-Ballart, J., Plana-Gil, N., Mendez-Marin, I., & Pareja-Rios, A. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.06.010 · Cited by 36
Predicting diabetic nephropathy in type 2 diabetic patients using machine learning algorithms
Hosseini Sarkhosh, S. M., Esteghamati, A., Hemmatabadi, M., & Daraei, M. (2022) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-022-01076-2 · Cited by 24
Metadata
- Authors
- de Boer, I. H.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2011-03-14
- Volume
- 171
- Issue
- 5
- Pages
- 412
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W1907964358
- Cited by
- 351
- References
- 39
- FWCI
- 24.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.